The tumour suppressor gene p53 is one of the most frequently mutated genes in lung cancer and these defects are associated with poor prognosis, albeit some debate exists in the lung cancer field. Despite extensive research, the exact mechanisms by which mutant p53 proteins promote the development and sustained expansion of cancer remain unclear. This review will discuss the cellular responses controlled by p53 that contribute to tumour suppression, p53 mutant lung cancer mouse models and characterisation of p53 mutant lung cancer. Furthermore, we discuss potential approaches of targeting mutant p53 for the treatment of lung cancer.
| Authors | Chen, T; Ashwood, LM; Kondrashova, O; Strasser, A; Kelly, G; Sutherland, KD |
|---|---|
| Journal | ONCOGENE |
| Pages | |
| Volume | |
| Date | 20/12/2024 |
| Grant ID | GNT2010275 | Department of Health | National Health and Medical Research Council (NHMRC); GNT2008631 | Department of Health | National Health and Medical Research Council (NHMRC); GNT1113133 | Department of Health | National Health and Medical Research Council (NHMRC); GNT1116937 | Department of Health | National Health and Medical Research Council (NHMRC); GNT 2002618 | Department of Health | National Health and Medical Research Council (NHMRC); GNT2001201 | Department of Health | National Health and Medical Research Council (NHMRC); GNT2011139 | Department of Health | National Health and Medical Research Council (NHMRC); MCRF17028 | Victorian Cancer Agency (VCA) |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1038/s41388-024-03219-6 |